HFM
ALNY icon

Hartford Financial Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Hartford Financial Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.1K Hold
100
– – 0.01% 229
2026
Q1 		$33.1K Hold
100
– – 0.01% 216
2025
Q4 		$39.8K Hold
100
– – 0.01% 201
2025
Q3 		$45.6K Hold
100
– – 0.01% 193
2025
Q2 		$32.6K Hold
100
– – 0.01% 215
2025
Q1 		$27K Hold
100
– – 0.01% 246
2024
Q4 		$23.5K Hold
100
– – ﹤0.01% 257
2024
Q3 		$27.5K Hold
100
– – 0.01% 256
2024
Q2 		$24.3K Buy
+100
New +$15.8K 0.01% 262

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hartford Financial Management's ALNY Position: Q2 2026 in Review

Hartford Financial Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 100 shares worth $30.1K. The position accounts for 0.01% of the portfolio, ranked #229.

Hartford Financial Management first reported a position in ALNY in Q2 2024 and has held it in 9 quarters since. The position peaked at $45.6K in Q3 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Hartford Financial Management held 100 shares of Alnylam Pharmaceuticals worth $30.1K as of Q2 2026.
  • Hartford Financial Management left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.01% of Hartford Financial Management's portfolio in Q2 2026, its #229 holding.
  • Hartford Financial Management first reported a position in Alnylam Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Hartford Financial Management's Alnylam Pharmaceuticals position peaked at $45.6K in Q3 2025.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Hartford Financial Management's 13F filing for Q2 2026, filed 24 Jul 2026.